Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Livanova Plc OR Sh (NQ: LIVN )

52.03 +0.71 (+1.38%)
Streaming Delayed Price Updated: 10:47 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Livanova Plc OR Sh

< Previous 1 2 3 Next >
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
From LivaNova PLC
Via Business Wire
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
From LivaNova PLC
Via Business Wire
LivaNova Reports Third-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
LivaNova Appoints Susan Podlogar as a New Director
From LivaNova PLC
Via Business Wire
LivaNova to Announce Third-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
LivaNova to Present at the Baird Global Healthcare Conference
From LivaNova PLC
Via Business Wire
LivaNova Reports Second-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
LivaNova to Announce Second-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
From LivaNova PLC
Via Business Wire
LivaNova to Present at the Goldman Sachs Healthcare Conference
From LivaNova PLC
Via Business Wire
LivaNova Reports First-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
From LivaNova PLC
Via Business Wire
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
From LivaNova PLC
Via Business Wire
LivaNova to Announce First-Quarter 2024 Results
From LivaNova PLC
Via Business Wire
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
From LivaNova PLC
Via Business Wire
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
From LivaNova PLC
Via Business Wire
LivaNova to Present at the Barclays Global Healthcare Conference
From LivaNova
Via Business Wire
LivaNova Reports Fourth-Quarter and Full-Year 2023 Results
From LivaNova PLC
Via Business Wire
LivaNova Announces Vladimir A. Makatsaria as CEO and Board Director
From LivaNova PLC
Via Business Wire
LivaNova to Wind Down Advanced Circulatory Support Business Unit
From LivaNova PLC
Via Business Wire
LivaNova to Announce Fourth-Quarter and Full-Year 2023 Results
From LivaNova PLC
Via Business Wire
LivaNova to Present at the Piper Sandler Healthcare Conference
From LivaNova PLC
Via Business Wire
LivaNova Reports Third-Quarter 2023 Results
From LivaNova PLC
Via Business Wire
LivaNova to Present at the Stifel and Wolfe Healthcare Conferences
From LivaNova PLC
Via Business Wire
LivaNova Board Appoints J. Christopher Barry as New Director
From LivaNova PLC
Via Business Wire
LivaNova Announces Marco Dolci, President of Cardiopulmonary, to Retire at the End of 2023
From LivaNova PLC
Via Business Wire
LivaNova to Announce Third-Quarter 2023 Results
From LivaNova PLC
Via Business Wire
LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark
From LivaNova PLC
Via Business Wire
LivaNova to Present at the Baird Global Healthcare Conference
From LivaNova PLC
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.